Abstract
ABSTRACT Adenosquamous carcinoma of the pancreas (ASCP) is a rare variant of the pancreatic ductal adenocarcinoma (PDAC). Between 2004 and 2016, four cases of ASCP were resected at our institution; clinicopathological data were collected. All of our patients were males, aged 55-80 years. Three cases were cephalic tumors; and one, pancreatic tail tumor, measuring between 2.3 and 5.5 cm. All had neurovascular invasion and lymphatic metastasis. Two had retroperitoneal positive margins. The overall survival (OS) after surgery was three weeks-42 months. Prognosis of ASCP is dark and OS appears to be more closely related to surgical margins status than to other clinicopathological factors.
Highlights
Pancreatic cancer (PC) is the fourth most fatal cancer in Europe, in both men and women[1]
adenosquamous carcinoma of the pancreas (ASCP) is referred to in the literature as adenoacanthoma, mixed squamous and adenocarcinoma, and mucoepidermoid carcinoma; it accounts for 1%-4% of all exocrine pancreatic tumors, being defined as a malignant epithelial neoplasm with both ductal and squamous differentiation, the latter accounting for at least 30% of tumor volume[3]
Adenosquamous carcinomas are seen in other organs: lung, esophagus, colon, stomach, salivary glands, and the female reproductive tract[5]
Summary
Pancreatic cancer (PC) is the fourth most fatal cancer in Europe, in both men and women[1]. With continuous rising of deaths, and incidence rates almost matching its mortality rate, it is a form of malignancy that causes great concern It mainly affects patients between 60 and 80 years of age, it shows a wide age range, and it is more common in males, with a male-female ratio of 1.5:1(2, 3). The World Health Organization (WHO) considers seven variants of pancreatic ductal adenocarcinoma (PDAC), being the adenosquamous carcinoma of the pancreas (ASCP) one of rarest, first described by Herxheimer, in 1907, using the term “adenocancroid”(3, 4). ASCP is referred to in the literature as adenoacanthoma, mixed squamous and adenocarcinoma, and mucoepidermoid carcinoma; it accounts for 1%-4% of all exocrine pancreatic tumors, being defined as a malignant epithelial neoplasm with both ductal and squamous differentiation, the latter accounting for at least 30% of tumor volume[3]. Two patients received adjuvant radio- and chemotherapy, one refused and the other had no adequate clinical status
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
